Iovance Biotherapeutics (IOVA) Gets a Buy from Barclays

Tip Ranks
2025.11.24 08:46
portai
I'm PortAI, I can summarize articles.

Barclays analyst Etzer Darout maintained a Buy rating on Iovance Biotherapeutics with a $9.00 price target. Darout, a 5-star analyst, focuses on healthcare stocks. Iovance also received a Buy from TD Cowen's Tyler Van Buren, while TR | OpenAI reiterated a Hold rating. Darout has a 25.0% average return and a 56.94% success rate.

Barclays analyst Etzer Darout maintained a Buy rating on Iovance Biotherapeutics today and set a price target of $9.00.

TipRanks Black Friday Sale

  • Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
  • Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off

According to TipRanks, Darout is a 5-star analyst with an average return of 25.0% and a 56.94% success rate. Darout covers the Healthcare sector, focusing on stocks such as Terns Pharmaceuticals, Exelixis, and CytomX Therapeutics.

In addition to Barclays, Iovance Biotherapeutics also received a Buy from TD Cowen’s Tyler Van Buren in a report issued on November 10. However, on November 21, TR | OpenAI – 4o reiterated a Hold rating on Iovance Biotherapeutics (NASDAQ: IOVA).

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer